Ascendis Pharma A/S (ASND)
| Market Cap | 13.71B +87.2% |
| Revenue (ttm) | 845.52M +98.0% |
| Net Income | -267.74M |
| EPS | -4.42 |
| Shares Out | 61.38M |
| PE Ratio | n/a |
| Forward PE | 40.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 633,558 |
| Open | 217.43 |
| Previous Close | 216.32 |
| Day's Range | 216.10 - 225.87 |
| 52-Week Range | 124.06 - 242.00 |
| Beta | 0.43 |
| Analysts | Strong Buy |
| Price Target | 277.13 (+24.05%) |
| Earnings Date | Feb 11, 2026 |
About ASND
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing o... [Read more]
Financial Performance
In 2025, Ascendis Pharma's revenue was 720.13 million, an increase of 98.03% compared to the previous year's 363.64 million. Losses were -228.03 million, -39.69% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price target is $277.13, which is an increase of 24.05% from the latest price.
News
Ascendis Pharma FY 2025 Results: More Than A Takeover Story
Ascendis Pharma has transitioned into a revenue-scaled commercial biotech, driven by Yorvipath's rapid adoption and strong FY25 results. ASND's 2025 product revenue surged to €684 million, with Yorvip...
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a...
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday...
Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones. Ascen...
Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript
Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
– Once-weekly TransCon ® CNP and TransCon ® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the 97th-p...
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 44th Annual J.P. Morgan Healthcare Conference ...
Here's My Prediction For Who Could Acquire Ascendis Pharma
Ascendis Pharma is rated a cautious buy amid acquisition speculation, robust revenue growth, and a pivotal FDA decision on TransCon CNP. Yorvipath and Skytrofa drove Q3 revenues to €213.6 million, nea...
Eight stock picks to play one of the healthiest corners of the market
The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull mar...
High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth
The Touchstone Mid Cap Growth Fund outperformed its benchmark, the Russell Midcap® Growth Index, for the quarter ended September 30, 2025. From a factor perspective, the Fund's overweight exposure to ...
Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ
The Investment Committee give you their top stocks to watch for the second half.
Ascendis: Q3 Results Validate The TransCon Platform
Ascendis Pharma has achieved operational profitability, driven by YORVIPATH's rapid adoption and strong Q3 2025 revenues of €213.6 million. ASND's robust cash position (€539 million) and self-sustaini...
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026
The U.S. Food & Drug Administration (FDA) on Tuesday extended review for Ascendis Pharma A/S‘ (NASDAQ: ASND) New Drug Application (NDA) for TransCon CNP (navepegritide) for children with achondroplasi...
US FDA extends review of Ascendis Pharma's therapy for children with dwarfism
The U.S. Food and Drug Administration on Tuesday extended its review of Ascendis Pharma's therapy for children with a rare genetic disorder that causes dwarfism, the company said.
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announ...
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics
COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Tri...
Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Chad Fugere Jan Mikkelsen - President, CEO, Member of Executive Board & Executive Director Scott Smi...
Ascendis Pharma Reports Third Quarter 2025 Financial Results
– Q3 2025 revenue of €143.1 million for YORVIPATH ® and €50.7 million for SKYTROFA ®
Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Ascendis Pharma A/S (NASDAQ:ASND) will release earnings results for the third quarter, after the closing bell on Wednesday, Nov. 12.
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism
COPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal fu...
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025
COPENHAGEN, Denmark, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wedne...
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025
COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of uri...
